| Identification | Back Directory | [Name]
SPLICEOSTATIN A | [CAS]
391611-36-2 | [Synonyms]
SPLICEOSTATIN A
XKSGIJNRMWHQIQ-CGPJBNNXSA-N
2-Pentenamide, 4-(acetyloxy)-N-[(2R,3R,5S,6S)-tetrahydro-6-[(2E,4E)-5-[(3R,4R,5R,7S)-4-hydroxy-7-methoxy-7-methyl-1,6-dioxaspiro[2.5]oct-5-yl]-3-methyl-2,4-pentadien-1-yl]-2,5-dimethyl-2H-pyran-3-yl]-, (2Z,4S)- | [Molecular Formula]
C28H43NO8 | [MDL Number]
MFCD22572777 | [MOL File]
391611-36-2.mol | [Molecular Weight]
521.64 |
| Chemical Properties | Back Directory | [Melting point ]
65-70 °C | [Boiling point ]
683.2±55.0 °C(Predicted) | [density ]
1.17±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
13.63±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Spliceostatin A, the FR901464 (HY-16212) methylated derivative, is a potent anti-tumor agent. Spliceostatin A inhibits splicing and promotes pre-mRNA accumulation by binding SF3B1. SF3B1 is a subcomplex of U2 small nuclear ribonucleoprotein in the spliceosome. Spliceostatin A induces Apoptosis in chronic lymphocytic leukemia (CLL) cells[1][2][3]. | [References]
[1] Larrayoz M, et al. The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1. Leukemia. 2016 Feb;30(2):351-60. DOI:10.1038/leu.2015.286
[2] Kaida D, et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol. 2007 Sep;3(9):576-83. DOI:10.1038/nchembio.2007.18
[3] Roybal GA, et al. Spliceostatin A inhibits spliceosome assembly subsequent to prespliceosome formation. Nucleic Acids Res. 2010 Oct;38(19):6664-72. DOI:10.1093/nar/gkq494 |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|